Novavax (NVAX) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Novavax (NVAX) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 21.7% versus a loss of 18.4%. Over five years, RXRX leads with a -77.6% price change compared with -93.1% for NVAX. Recursion Pharmaceuticals is the larger company by market cap ($2.12 billion vs $1.80 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | RXRX |
|---|---|---|
| Share price | $10.92 | $3.95 |
| Market cap | $1.80B | $2.12B |
| 1-day change | -2.72% | -7.53% |
| YTD return | +66.96% | +4.40% |
| 1-year return | +21.69% | -18.36% |
| 5-year return | -93.07% | -77.57% |
| EPS (TTM) | $-1.58 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.39 | $7.18 |
| 52-week low | $6.20 | $2.77 |
| Distance from 52-week high | -18.48% | -45.00% |
| Analyst consensus | buy | none |
| Avg. price target upside | +28.26% | +82.84% |
| Average volume | 5.16M | 20.56M |
| Shares outstanding | 164.95M | 535.34M |
| Employees | 749 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed RXRX by 40.0 percentage points over the past year.
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
NVAX vs RXRX FAQ
Which is bigger, Novavax or Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.12B compared with $1.80B for Novavax (NVAX).
Which stock has performed better over the past year, NVAX or RXRX?
NVAX returned +21.69% over the past 12 months, compared with -18.36% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Novavax and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.